Drug Discovery World

APRIL 16, 2023

He is being recognised for his ‘revolutionary’ contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 52

Clinical Trials Clinical Trials Research Vaccination 52

XTalks

AUGUST 2, 2023

It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. This growth was propelled by the expansion of its development portfolio in cell and gene therapies, as well as advancements in late-stage pharmaceutical pipeline drugs like asundexian and elinzanetant. Astellas Pharma Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 24, 2021

CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. The drug was well tolerated and demonstrated clinically meaningful improvement in the Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure IPOEM).

Trials 52

Trials Allergies In-Vitro Antibody 52